Jagsonpal Pharmaceuticals Performance Analyzed

Jagsonpal Pharmaceuticals had a tough quarter. Their sales dropped by 1.46%, falling to Rs 72.95 crore. This is a significant change from the previous quarter when sales were Rs 74.03 crore.

Key Points

• Sales decreased by 1.46% to Rs 72.95 crore.
• Net profit plummeted 65.77% to Rs 10.95 crore.
• Operating profit (OPM) decreased to 22.30% from 21.38%.
• Profit Before Tax (PBDT) rose by 6% to Rs 18.99 crore.
• Profit After Tax (PBT) increased by 7% to Rs 16.60 crore.
• Net Profit (NP) fell dramatically to Rs 10.95 crore.

The biggest problem was with their profit. Net profit saw a huge decrease of 65.77%, dropping down to Rs 10.95 crore. This is much lower than the Rs 31.99 crore they made in the previous quarter.

Looking at the numbers, their profit before tax (PBDT) did improve slightly by 6% to Rs 18.99 crore. However, the profit after tax (PBT) also increased by 7% to Rs 16.60 crore. Despite these small positive changes, the overall impact of the sales decline and significant profit reduction is concerning.

It’s important to understand what caused these changes. The company’s operating margin (OPM), which measures how much profit they make for every rupee of sales, dropped to 22.30% compared to 21.38% before. This indicates pressure on their business operations.

The decline in net profit to Rs 10.95 crore is a major worry for investors. It shows a sharp reduction in the company’s ability to generate earnings.

Ultimately, Jagsonpal Pharmaceuticals needs to address the reasons for declining sales and improving profitability.